Clinical Trial Update: A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial (AZURE-2) comparing Brelovitug (BJT-778) to bulevirtide for chronic hepatitis D infection is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis D

Drugs mentioned

• Brelovitug (BJT-778)
• Bulevirtide (bulevirtide)

Snippet

Sponsor: Mirum Pharmaceuticals, Inc. | Conditions: Chronic Hepatitis D Infection | Phase 3 | Status: RECRUITING